|
|
|
Volumn 25, Issue 6, 2011, Pages 1-5
|
|
Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
QUINAZOLINE DERIVATIVE;
ARTICLE;
BIOMEDICAL TECHNOLOGY ASSESSMENT;
DISEASE COURSE;
DRUG ANTAGONISM;
GENETICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
MUTATION;
PERSONALIZED MEDICINE;
TREATMENT OUTCOME;
CARCINOMA, NON-SMALL-CELL LUNG;
DISEASE PROGRESSION;
HUMANS;
INDIVIDUALIZED MEDICINE;
LUNG NEOPLASMS;
MUTATION;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
QUINAZOLINES;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TECHNOLOGY ASSESSMENT, BIOMEDICAL;
TREATMENT OUTCOME;
|
|
EID: 79958256783
PISSN: None
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (1)
|
|
References (0)
|